MX2020013389A - Composiciones de terlipresina y usos de las mismas. - Google Patents

Composiciones de terlipresina y usos de las mismas.

Info

Publication number
MX2020013389A
MX2020013389A MX2020013389A MX2020013389A MX2020013389A MX 2020013389 A MX2020013389 A MX 2020013389A MX 2020013389 A MX2020013389 A MX 2020013389A MX 2020013389 A MX2020013389 A MX 2020013389A MX 2020013389 A MX2020013389 A MX 2020013389A
Authority
MX
Mexico
Prior art keywords
terlipressin
compositions
terlipressin compositions
pharmaceutical compositions
therapeutic methods
Prior art date
Application number
MX2020013389A
Other languages
English (en)
Spanish (es)
Inventor
Mattias Malm
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MX2020013389A publication Critical patent/MX2020013389A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/095Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/085Angiotensins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2020013389A 2018-06-15 2019-06-14 Composiciones de terlipresina y usos de las mismas. MX2020013389A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862685447P 2018-06-15 2018-06-15
PCT/IB2019/055004 WO2019239386A1 (en) 2018-06-15 2019-06-14 Terlipressin compositions and uses thereof

Publications (1)

Publication Number Publication Date
MX2020013389A true MX2020013389A (es) 2021-03-31

Family

ID=67742882

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013389A MX2020013389A (es) 2018-06-15 2019-06-14 Composiciones de terlipresina y usos de las mismas.

Country Status (9)

Country Link
US (1) US11931398B2 (https=)
EP (1) EP3806823A1 (https=)
JP (2) JP7523775B2 (https=)
CN (1) CN112969449B (https=)
BR (1) BR112020025380A2 (https=)
CA (1) CA3103215A1 (https=)
MX (1) MX2020013389A (https=)
TW (1) TW202003548A (https=)
WO (1) WO2019239386A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220080023A1 (en) * 2018-12-21 2022-03-17 Arecor Limited Novel composition
KR20220011697A (ko) 2019-05-22 2022-01-28 바이오비에 아이앤씨. 테를리프레신 제형
CN114177147B (zh) * 2021-12-15 2023-05-23 福建省闽东力捷迅药业股份有限公司 一种注射用特利加压素的制备方法以及制得的注射用特利加压素
US20240156895A1 (en) * 2022-10-28 2024-05-16 Mallinckrodt Pharmaceuticals Ireland Limited Compositions for improving kidney function in patients with hepatorenal syndrome

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
CN1244794A (zh) * 1997-11-06 2000-02-16 奥尔班公司 用于药物释放的稳定的干燥药物组合物及其制备方法
RU2415149C2 (ru) * 2006-02-10 2011-03-27 Ферринг Б.В. Пептидные соединения
CN102068685A (zh) * 2010-04-09 2011-05-25 深圳翰宇药业股份有限公司 一种特利加压素制剂及其制备方法
CN102440957B (zh) 2011-12-16 2013-09-25 深圳市健元医药科技有限公司 醋酸特利加压素鼻腔喷雾剂及其制备方法
CN104334117A (zh) 2012-01-26 2015-02-04 恩多沙普公司 用远端和/或近端控制来输送管腔闭塞装置的系统、装置和方法
AR091902A1 (es) * 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
CN105592855A (zh) * 2013-04-26 2016-05-18 拉卓拉药物公司 用于治疗肾衰竭的组合物和方法
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
CN106188218B (zh) * 2016-07-14 2018-11-23 江苏诺泰澳赛诺生物制药股份有限公司 一种提高多肽原料药稳定性的方法
GB201721846D0 (en) 2017-12-22 2018-02-07 Arecor Ltd Novel composition
KR20220011697A (ko) 2019-05-22 2022-01-28 바이오비에 아이앤씨. 테를리프레신 제형

Also Published As

Publication number Publication date
US20210161995A1 (en) 2021-06-03
JP2024086898A (ja) 2024-06-28
US11931398B2 (en) 2024-03-19
CN112969449B (zh) 2025-03-11
CN112969449A (zh) 2021-06-15
JP7523775B2 (ja) 2024-07-29
EP3806823A1 (en) 2021-04-21
WO2019239386A1 (en) 2019-12-19
JP2021527084A (ja) 2021-10-11
TW202003548A (zh) 2020-01-16
BR112020025380A2 (pt) 2021-05-18
CA3103215A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
MX2025003235A (es) Composiciones y metodos para el suministro de proteinas de membrana
PH12020551716A1 (en) Anti-ror antibody constructs
IL276464A (en) Methods and preparations for administering therapeutic protein
EP4620519A3 (en) Methods and compositions relating to chondrisomes from blood products
MX2022004304A (es) Agentes inductores de apoptosis.
MX2023011657A (es) Composiciones que comprenden curones y usos de los mismos.
MX2024004386A (es) Dianas terapeuticas para la correccion del gen de la distrofina humana por edicion genica y metodos de uso.
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
MY191581A (en) Anti-pd-1 antibodies
SA518391831B1 (ar) تركيبات وطرق لخفض تعبير البروتين تاو
GB2541571A (en) Pharmaceutical compositions
MX2017011997A (es) Carbamatos de piperacina y metodos de preparacion y uso.
MX2025010681A (es) Formulaciones transdermicas
EP4599893A3 (en) Cg0070 for treating bcg resistant bladder carcinoma in situ
ZA201807438B (en) Methods of treating ocular conditions
WO2018226992A8 (en) Tau aggregation inhibitors
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
PH12017500602A1 (en) Methods for treating ocular conditions
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
JOP20190164B1 (ar) تركيبات وطرق لعلاج داء فاربر
PH12020551618A1 (en) Erenumab compositions and uses thereof
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
MX2019014475A (es) Formulaciones de lixivaptan para el tratamiento de enfermedades poliquisticas.
HK40042312A (en) Methods and compositions for therapeutic protein delivery